CS
EWTX icon

Candriam SCA’s Edgewise Therapeutics EWTX Stock Holding History

Candriam SCA’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-447,416
Closed -$14.1M – 694
2026
Q1 		$14.1M Sell
447,416
-53,798
-11% -$1.55M 0.07% 232
2025
Q4 		$12.4M Buy
501,214
+280,055
+127% +$5.62M 0.06% 243
2025
Q3 		$3.59M Sell
221,159
-2,831
-1% -$40.2K 0.02% 407
2025
Q2 		$2.94M Sell
223,990
-1,806
-0.8% -$26K 0.02% 435
2025
Q1 		$4.97M Sell
225,796
-28,169
-11% -$739K 0.03% 329
2024
Q4 		$6.78M Sell
253,965
-40,659
-14% -$1.29M 0.04% 314
2024
Q3 		$7.86M Sell
294,624
-34,376
-10% -$684K 0.05% 298
2024
Q2 		$5.93M Hold
329,000
– – 0.04% 318
2024
Q1 		$6M Buy
329,000
+21,000
+7% +$334K 0.04% 311
2023
Q4 		$3.37M Buy
308,000
+10,000
+3% +$70.2K 0.02% 395
2023
Q3 		$1.71M Hold
298,000
– – 0.01% 471
2023
Q2 		$2.31M Hold
298,000
– – 0.02% 472
2023
Q1 		$1.83M Hold
298,000
– – 0.01% 594
2022
Q4 		$2.66M Buy
298,000
+108,000
+57% +$1.01M 0.02% 522
2022
Q3 		$1.87M Buy
+190,000
New +$1.92M 0.01% 594

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Candriam SCA's EWTX Position: Q2 2026 in Review

Candriam SCA sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 447,416 shares — an estimated $14.1M sold.

Candriam SCA first reported a position in EWTX in Q3 2022 and held it in 15 quarters. The position peaked at $14.1M in Q1 2026. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Candriam SCA reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Candriam SCA sold 447,416 Edgewise Therapeutics shares in Q2 2026, an estimated $14.1M.
  • Candriam SCA first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 15 quarters.
  • Candriam SCA's Edgewise Therapeutics position peaked at $14.1M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.